Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 6, 2026, 9:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Poractant alfa Clear all

Conditions: Premature Lungs, Respiratory Distress Syndrome, Surfactant Deficiency Syndrome Neonatal
Interventions: Less Invasive Surfactant Administration LISA, Continuous Positive Airway Pressure CPAP; Procedure
Lead sponsor: Sharp HealthCare; Other
Eligibility: 24 Weeks to 29 Weeks
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Irvine, California • Loma Linda, California • San Diego, California

Conditions: Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
Interventions: budesonide (Pulmicort nebulizing suspension)., surfactant (poractant alfa;Curosurf); Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 48 Hours
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 19
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more

Conditions: Acute Respiratory Distress Syndrome
Interventions: CUROSURF® (poractant alfa); Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Respiratory Distress Syndrome
Interventions: Poractant alfa, calfactant; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 22 Weeks to 35 Weeks
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Congenital Heart Disease, Hypoplastic Left Heart Syndrome
Interventions: Curosurf, Sham; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 1 Day to 12 Weeks
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Bronchopulmonary Dysplasia
Interventions: Minimally invasive surfactant therapy, Continuation on CPAP; Device · Other
Lead sponsor: Menzies Institute for Medical Research; Other
Eligibility: 1 Minute to 6 Hours
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 5
States / cities: New Haven, Connecticut • Honolulu, Hawaii • Evanston, Illinois + 2 more

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: CHF5633, Poractant alfa; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 1 Hour to 24 Hours
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Mobile, Alabama • Los Angeles, California • Orange, California + 20 more

Conditions: Respiratory Distress Syndrome
Interventions: Curosurf®, Survanta®; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 15 Minutes to 12 Hours
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Prematurity, Respiratory Distress Syndrome, Patent Ductus Arteriosus
Interventions: Survanta (beractant), Curosurf (poractant); Drug
Lead sponsor: Alan Fujii; Other
Eligibility: Up to 8 Hours
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Extreme Prematurity, Respiratory Distress Syndrome
Interventions: LISA; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 5 Minutes to 20 Minutes
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Respiratory Distress Syndrome (Neonatal), Surfactant
Interventions: Surfactant Administration Through Laryngeal or Supraglottic Airway (SALSA), Continuous Positive Airway Pressure (CPAP); Procedure
Lead sponsor: Sharp HealthCare; Other
Eligibility: 33 Weeks to 38 Weeks
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: Chula Vista, California • La Mesa, California • San Diego, California

Conditions: Respiratory Distress Syndrome
Interventions: MIST surfactant; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: Up to 48 Hours
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Respiratory Distress Syndrome
Interventions: Nasal continuous positive airway pressure (nCPAP), Laryngeal Mask Airway (LMA) to deliver surfactant, Surfactants, Pulmonary; Device · Drug
Lead sponsor: University of Minnesota; Other
Eligibility: Up to 36 Hours
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: Loma Linda, California • San Diego, California • Maple Grove, Minnesota + 4 more

Conditions: Respiratory Distress Syndrome, Newborn, Premature Birth
Interventions: Poractant Alfa; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: Up to 15 Minutes
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Respiratory Distress Syndrome (RDS)
Interventions: LISA combination product (Curosurf+catheter CHF6440), Curosurf through conventional administration (endotracheal tube); Combination Product · Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 30 Minutes to 24 Hours
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 26
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 22 more

Search by objective public record fields.

Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants

The Budesonide in Babies (BiB) Trial

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome

Cold Heart Study: A Randomized Pilot Trial of Surfactant Therapy

OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP

A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)

Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome

Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants

LISA in the Delivery Room for Extremely Preterm Infants

Surfactant Using a Supraglottic Airway Device in Late Preterm to Early Term Infants

Non Inferiority Trial Investigating Surfactants Administered Via MIST

Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates

Prophylactic Minimally Invasive Surfactant Evaluation

A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration